Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (1282)	2/7/1999 11:09:00 PM
From: Alex Glavinos	Respond to of 1510

John, I agree IRC has a lot of good science going for them. I'm a a believer in small biotech companies. I invested in DSCO, LGND, XOMA and IMNR, because I believe that's where the ideas come from. I'm also a realist. Drug trials are a very expensive proposition. The FDA process is costly and lengthy. That's why so many of these small companies partner with the big ones. I hope IMNR can remain independent. I believe that was Dr. Salks intentions. A case in point is AGPH. Many of the stock holders didn't want to see the WLA buy out. Cheers Alex